CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.

J Am Heart Assoc · 2014 · PMC4187475 · PMID 24755152

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

20 Immunohistochemical analysis revealed that IL‐2 complex monotherapy did not affect the number of CD4 + T cells in atherosclerotic plaques, whereas CD3‐Ab monotherapy or combination therapy showed a trend toward reduction in CD4 + T cell infiltration compared with control mice (Figures 4 A and 4 B).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.